Völz S, Petursson P, Odenstedt J, et al. - Researchers investigated if treatment with ticagrelor is superior to clopidogrel in unselected patients suffering from acute coronary syndromes managed with percutaneous coronary intervention (PCI). For this purpose, they utilized data from SCAAR (Swedish Coronary Angiography and Angioplasty Registry) for PCI done in Västra Götaland County, Sweden. Death or stent thrombosis at 30 days was the primary combined endpoint. This study involved 15,097 patients, of which, 2,929 (19.4%) received ticagrelor. Therapy with ticagrelor was not related to a lower risk for the primary endpoint. A higher risk of in‐hospital bleeding was observed in correlation with treatment with ticagrelor. Overall, findings of this observational analysis revealed that ticagrelor was not superior to clopidogrel as a therapeutic choice for patients with acute coronary syndromes managed with PCI.